Sutent (sunitinib)

DRUG2 trials

Sponsors

California Pacific Medical Center Research Institute, National Cancer Institute (NCI)

Conditions

Anaplastic GliomasGlioblastoma MultiformeMalignant GliomasMetastatic Melanoma

Phase 2

Clinical Trial of Sutent to Treat Metastatic Melanoma

CompletedNCT00631618

California Pacific Medical Center Research InstituteMetastatic Melanoma

Start: 2007-09-30End: 2012-03-31Updated: 2014-02-25

Sunitinib to Treat Recurrent Brain Cancer

TerminatedNCT00923117

National Cancer Institute (NCI)Anaplastic Gliomas, Glioblastoma Multiforme, Malignant Gliomas

Start: 2008-06-30End: 2012-06-30Updated: 2015-09-30